AG003I2X

21256-18-8 | 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid

AG003I2X

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	21256-18-8
Catalog Number	AG003I2X(AGN-PC-0JK6Y5)
Chemical Name	3-(diphenyl-1,3-oxazol-2-yl)propanoic acid
EC Number	244-296-1
IUPAC Name	3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
InChI	InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
InChI Key	OFPXSFXSNFPTHF-UHFFFAOYSA-N
MDL Number	MFCD00215977
Molecular Formula	C18H15NO3
Molecular Weight	293.3166
SMILES	O=C(O)CCC1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)O1
UNII	MHJ80W9LRB
Synonyms	4,5 Diphenyl 2 oxazolepropionic Acid, 4,5-diphenyl-2-oxazolepropionic acid, Apo Oxaprozin, Apo-Oxaprozin, Danoprox, Daypro, Dayrun, oxaprozin, Rhoxal oxaprozin, Rhoxal-oxaprozin, Wy 21,743, Wy-21,743, oxaprozin, 21256-18-8, Daypro, Alvo, Oxaprozine, Oxaprozinum, 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid, 3-(4,5-Diphenyloxazol-2-yl)propanoic acid, Deflam, Oxaprozina, Voir, Oxaprozine [INN-French], Oxaprozinum [INN-Latin], WY-21743, Oxaprozina [INN-Spanish], 4,5-Diphenyl-2-oxazolepropionic acid, WY-21,743, 4,5-Diphenyl-2-oxazolepropanoic acid, 2-Oxazolepropanoic acid, 4,5-diphenyl-, WY 21743, NSC310839, 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid, beta-(4,5-Diphenyloxazol-2-yl)propionic acid, UNII-MHJ80W9LRB, MFCD00215977, MHJ80W9LRB, NSC 310839, CHEMBL1071, CHEBI:7822, 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid, C18H15NO3, 2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL-, OFPXSFXSNFPTHF-UHFFFAOYSA-N, .beta.-(4,5-Diphenyloxazol-2-yl)propionic acid, EINECS 244-296-1, NSC-310839, BRN 1083168, Danoprox, Dayrun, 3-(4,5-Diphenyl-2-oxazolyl)propanoic acid, CAS-21256-18-8, DSSTox_CID_25118, DSSTox_RID_80684, DSSTox_GSID_45118, Actirin, Xopane, SMR000058286, Daypro (TN), SR-01000076053, oxaprosin, Durapro, Duraprost, Oxaprozi, Oxapro, Walix, Oxaprozin, solid, Oxaprozin [USAN:BAN:INN:JAN], Oxaprozin,(S), NCI310839, 4, 5-Diphenyl-2-oxazolepropionic acid, Maybridge1_008800, Prestwick0_001060, Prestwick1_001060, Prestwick2_001060, Prestwick3_001060, Spectrum2_001696, Spectrum3_001078, Spectrum4_001231, Lopac-O-9637, O 9637, AC1L1IK7, SCHEMBL3286, NCIStruc1_000799, NCIStruc2_000787, BIDD:PXR0149, Lopac0_000944, Oprea1_509470, BSPBio_001020, BSPBio_002696, KBioGR_001722, MLS000759535, MLS001424072, BIDD:GT0438, SPECTRUM1505267, SPBio_001652, SPBio_002940, AC1Q759J, AC1Q759K, BPBio1_001122, GTPL7252, Oxaprozin (JP17/USAN/INN), DTXSID1045118, CTK7J3117, HMS566H22, HSDB 7586, KBio3_001916, KS-00000ULR, HMS1571C22, HMS1922P17, HMS2051L15, HMS2093O08, HMS2098C22, HMS3262N10, HMS3393L15, HMS3652H17, HMS3715C22, Pharmakon1600-01505267, Wy21743, BCP28431, HY-B0808, Tox21_110059, Tox21_500944, 2-Oxazolepropanoic acid,5-diphenyl-, 2-Oxazolepropionic acid,5-diphenyl-, ANW-63377, BDBM50002861, CCG-36508, NCGC00014711, NSC758949, s4230, SBB053166, ZINC49643479, 4,5-diphenyloxazole-2-propanoic acid, 4,5-Diphenyloxazole-2-propionic acid, AKOS000206807, Oxaprozin [USAN:USP:INN:BAN:JAN], Tox21_110059_1, CS-7975, DB00991, KS-5196, LP00944, MCULE-7099031811, NC00214, NSC-758949, NCGC00014711-01, NCGC00014711-02, NCGC00014711-03, NCGC00014711-04, NCGC00014711-05, NCGC00014711-06, NCGC00014711-07, NCGC00014711-08, NCGC00014711-09, NCGC00014711-10, NCGC00014711-11, NCGC00014711-14, NCGC00014711-15, NCGC00094249-01, NCGC00094249-02, NCGC00094249-03, NCGC00094249-04, NCGC00094249-05, NCGC00094249-06, NCGC00094249-07, NCGC00261629-01, AC-26512, AJ-08102, AK-84489, CPD000058286, NCI60_002681, SAM001246770, SC-13926, SBI-0050918.P002, AB0011812, LS-100216, TC-152122, 3-(4,5-Diphenyl-2-oxazolyl)propionic acid, AB00514024, B1804, EU-0100944, FT-0638104, O0377, ST50949623, SW197319-4, 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid, EN300-25629, 3-(4,5-Diphenyl-oxazol-2-yl)-propionic acid, 4.5-Diphenyl-2-oxazolepropanoic acid|||Daypro, C07356, D00463, J10396, K-6109, AB00514024_08, AB00514024_09, 256O188, A815225, I14-8703, J-013955, SR-01000076053-1, SR-01000076053-3, SR-01000076053-7, SR-01000076053-9, 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid #, BRD-K25394294-001-05-7, BRD-K25394294-001-08-1, Z217102860, Oxaprozin, United States Pharmacopeia (USP) Reference Standard, Duraprox, Apo-Oxaprozin, Rhoxal-oxaprozin, Apo Oxaprozin, Rhoxal oxaprozin, Daypro Alta, lyl)propenoic acid, Oxaprozin Potassium, Duraprox (TN), CSC brand of oxaprozin, TRB brand of oxaprozin, Apotex brand of oxaprozin, Pfizer brand of oxaprozin, D0M9DC, Rhoxalpharma brand of oxaprozin, 3-(4, 5-Diphenyl-2-oxazo, Oxaprozin (JP15/USAN/INN), CID4614, 4,5 Diphenyl 2 oxazolepropionic Acid, CS-O-02038, Wy 21,743, C008729, D000077431, Oxaprozin, 98%, a pancreatic and gastric lipase inhibitor and caspase-3 activator - 25G 25g,

Complexity	361
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Exact Mass	293.105g/mol
Formal Charge	0
Heavy Atom Count	22
Hydrogen Bond Acceptor Count	4
Hydrogen Bond Donor Count	1
Isotope Atom Count	0
Molecular Weight	293.322g/mol
Monoisotopic Mass	293.105g/mol
Rotatable Bond Count	5
Topological Polar Surface Area	63.3A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	4.2

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302+H312+H332
Packing Group
Precautionary statements	P280
UN Code

Certificate of Analysis

Lot Number